A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.
NCT ID: NCT06205732
Last Updated: 2024-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2024-01-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma
NCT05247996
TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
NCT06487663
Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
NCT06540508
TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma
NCT02529761
Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
NCT02873442
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TACE+PD-(L)1+TKI
Application of TACE, TKI, and immunotherapy in patients with intermediate and advanced liver cancer.
Immunotherapy, targeted therapy.
Immunotherapy (sintilimab, camrelizumab, tislelizumab, atezolizumab, durvalumab, cardenilumab, and pembrolizumab); targeted therapy (apatinib, lenvatinib, sorafenib, and regorafenib).
TACE alone
Application of TACE in patients with intermediate and advanced liver cancer.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Immunotherapy, targeted therapy.
Immunotherapy (sintilimab, camrelizumab, tislelizumab, atezolizumab, durvalumab, cardenilumab, and pembrolizumab); targeted therapy (apatinib, lenvatinib, sorafenib, and regorafenib).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* primary liver cancer confirmed by liver biopsy or history of hepatitis B, AFP, and typical imaging findings
* patients with liver function Child-Pugh A or B (≤8 points)
* BCLC stage B and stage C
* expected survival time ≥8 weeks
* patients with generally good performance status (ECOG PS score 0 or 1)
Exclusion Criteria
* liver metastatic cancer confirmed by histology or cytology
* patients who interrupt treatment due to intolerance of adverse drug reactions
* combined with primary malignant tumors of other organs within 5 years; combined with other serious diseases, such as severe heart disease, renal insufficiency, severe infection, bleeding, etc.
* combined with systemic infection, autoimmune disease, or other types of tumors; previous allogeneic bone marrow transplantation or solid organ transplantation
* study participants known to have mental illness
* situations such as drug use or substance abuse
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qianfoshan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jing Liang, Dr
Role: STUDY_DIRECTOR
the Qianfoshan Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
the Qianfoshan Hospital
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YXLL-KY-2023(145)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.